Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LATS1 | O95835 | 1/20 | 0.34 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768444 | 1.00 | HTT (0.37) | HTTLATS1LATS2NCOA3ESR2 | |
| SCHEMBL29572040 | 0.90 | HTT (0.37) | HTTLATS1LATS2NCOA3ESR2 | |
| SCHEMBL4119052 | 0.90 | HTT (0.37) | HTTLATS1LATS2NCOA3ESR2 | |
| SCHEMBL17541690 | 0.81 | LATS1 (0.37) | HTTLATS1LATS2NCOA3KMT2A | |
| SCHEMBL31663361 | 0.78 | ESR2 (0.31) | ESR2 | |
| SCHEMBL27191758 | 0.78 | ESR2 (0.31) | ESR2 | |
| SCHEMBL2352761 | 0.77 | LPL (0.34) | LPLLIPG | |
| SCHEMBL520252 | 0.77 | LPL (0.42) | HTTESR2LPLLIPGALDH1A1 | |
| SCHEMBL29515710 | 0.77 | LPL (0.34) | LPLLIPG | |
| SCHEMBL2631244 | 0.77 | LPL (0.34) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688785-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | Beone Medicines I GmbH (CH) | 2026-02-11 | — | — | EP | disclosed |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| US-12466815-B2 | Carboxamide compounds and uses thereof | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-02-13 | — | — | US | disclosed |
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| US-20240368177-A1 | 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| WO-2024199255-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-03 | — | — | WO | disclosed |
| US-9695175-B2 | Highly selective c-Met inhibitors as anticancer agents | CB THERAPEUTICS INC. (KY) | 2017-07-04 | — | — | US | disclosed |
| US-9150592-B2 | Heterocyclic nuclear hormone receptor modulators | ABBVIE INC. (US) | 2015-10-06 | — | — | US | disclosed |
| EP-2651931-B1 | FUSED DIHYDROPYRANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | APOLLOMICS INC. | 2015-08-06 | — | — | US | disclosed |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8669271-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-11 | — | — | US | disclosed |
| EP-2651931-A1 | FUSED DIHYDROPYRANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2013-10-23 | — | — | EP | disclosed |
| US-20120322784-A1 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012086735-A1 | CONDENSED HETEROCYCLIC COMPOUND | 大正製薬株式会社 (JP) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012080476-A1 | FUSED DIHYDROPYRANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322784-A1 | Compounds, pharmaceutical compositions and uses thereof | GPR119, GPR3, MRGPRX2 | HTT 3042/4885LATS1 4409/4885LATS2 4026/4885 |
| US-20140179676-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | NR5A2, NR5A1, GPER1 | HTT 2354/4885LATS1 3475/4885LATS2 3832/4885 |
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | HTT 1905/4885LATS1 2467/4885LATS2 2724/4885 |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | HTT 2374/4885LATS1 1296/4885LATS2 1364/4885 |
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | MET, MYC, HGFAC | HTT 3716/4885LATS1 440/4885LATS2 739/4885 |
| US-20240368177-A1 | 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | PRMT5, PRMT6, PRMT1 | HTT 3651/4885LATS1 2984/4885LATS2 3016/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | HTT 860/4885LATS1 359/4885LATS2 424/4885 |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | HTT 3160/4885LATS1 798/4885LATS2 863/4885 |
| US-12466815-B2 | Carboxamide compounds and uses thereof | PCK1, PHKG2, PHKG1 | HTT 2370/4885LATS1 2364/4885LATS2 2560/4885 |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | HTT 2281/4885LATS1 4362/4885LATS2 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.